Kairos Pharma公布了其药物Env-105在针对EGFR突变肺癌患者的一期临床试验中取得的突破性中期安全性数据。该研究旨在攻克一个价值高达百亿美元的肿瘤耐药市场,为应对棘手的药物耐药性难题提供了新的潜在解决方案。此次积极的安全性数据为后续的疗效评估和开发进程奠定了重要基础,有望为现有治疗选择有限的患者群体带来新的希望。
Kairos Pharma公布了其药物Env-105在针对EGFR突变肺癌患者的一期临床试验中取得的突破性中期安全性数据。该研究旨在攻克一个价值高达百亿美元的肿瘤耐药市场,为应对棘手的药物耐药性难题提供了新的潜在解决方案。此次积极的安全性数据为后续的疗效评估和开发进程奠定了重要基础,有望为现有治疗选择有限的患者群体带来新的希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.